<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01294592</url>
  </required_header>
  <id_info>
    <org_study_id>114615</org_study_id>
    <nct_id>NCT01294592</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement</brief_title>
  <acronym>CONDUCT</acronym>
  <official_title>Comparative Efficacy of Dutasteride Plus Tamulsoin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the
      efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful
      waiting, with a defined escalation to tamsulosin in treatment naive men with symptomatic
      benign prostate hyperplasia (BPH).

      Once consented, each subject will undergo screening procedures to ensure the prostate volume
      and post void residual are within eligible range. If all entry criteria are met, subjects
      will be randomised (1:1) to receive Dutasteride plus tamsulosin with lifestyle advice or
      watchful waiting, with lifestyle advice, with a defined escalation to tamsulosin. Escalation
      will be initiated when no improvement from baseline is scored using the International
      Prostate Symptom Score (version 2) (IPSS) questionnaire.

      After randomisation, the subjects return to site at one month, then every 13 weeks until two
      years of treatment is complete or they are withdrawn. Key assessments, such as Adverse Events
      (AE's) and concomitant medication monitoring and completion of the quality of life
      questionnaires are performed at each visit and the data recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a European, multicentre, randomised, open-label, parallel group study. The aim
      of the study is to investigate whether Dutasteride plus Tamulson treatment with lifestyle
      advice is more effective than watchful waiting treatment plus lifestyle advice plus step-up
      therapy with tamsulosin for improvement of symptoms and Acte Urinary Retention (AUR) and
      BPH-related prostatic surgery, in older men (≥50 yrs), with moderate symptoms of BPH (IPSS
      8-19), enlarged prostates (≥30cc) and Prostate Specific Antigen (PSA) ≥1.5ng/mL.

      Data from all participating centres will be pooled prior to analysis. Investigative centres
      will be pooled a priori into clusters based on geographic location; these clusters may be
      used in analyses to adjust for site effects. Clusters will be defined once all investigative
      centres have been identified and randomisation has been completed.

      Subjects will be screened for inclusion into the study and eligible subjects will be
      randomised by investigative centre. Subjects will be allocated to one of two treatment
      groups, according to a pre-determined randomisation schedule (in a 1:1 ratio):

        -  Dutasteride plus tamsulosin once daily plus lifestyle advice.

        -  Watchful waiting plus lifestyle advice. Escalation to tamsulosin 0.4 mg once daily at
           any visit from Week 4 if any IPSS measurement shows no improvement or worsening from
           baseline. At any study visit, if the IPSS is the same or greater than the baseline value
           for that subject, tamsulosin 0.4 mg once daily will be initiated. If tamsulosin is
           initiated, it will be continued for the remainder of the study unless the subject elects
           to withdraw from the study. Initiation of tamsulosin will be recorded in the electronic
           case report form (eCRF.) Subjects will self-administer study medication once daily for
           up to 104 weeks, (up to 100 weeks for those on tamsulosin). Subjects will return to the
           clinic at 4 weeks post-randomisation and then at 13-week intervals post-randomisation
           during the 2-year treatment period (i.e. at 4, 13, 26, 39, 52, 65, 78, 91 and 104 weeks)
           for the assessments listed as in Appendix 1 Time and Events Schedule.

      Approximately 760, treatment naive men with symptomatic BPH will be randomised into the study
      in order to achieve at least 592 evaluable subjects. 380 into the Dutasteride plus tamsulosin
      with lifestyle advice arm and 380 into the watchful waiting plus lifestyle advice arm.

      Treatment naïve is defined as a man that has recently been diagnoses with BPH whom has
      received no prescribed therapeutic treatment. For example, medicines such as 5 α-reductase
      inhibitors (5-ARIs) or invasive procedures such as transurethral resection of the prostate
      (TURP) prescribed to directly treat the BPH symptoms are considered therapeutic treatments.
      As per the entry criteria, phytotherapy is allowed unless it was performed less than two
      weeks prior to the screening visit.

      The anticipated recruitment period will be approximately 6 months. The study will be
      conducted in approximately 8 countries within Europe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward (LOCF) Approach</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
    <description>The IPSS questionnaire is a 7-item self-administered questionnaire designed to quantify the following urinary symptoms: Question 1 (Q1), incomplete emptying; Q2, frequency; Q3, intermittency; Q4, urgency; Q5, weak stream; Q6, straining; Q7, nocturia. It has an additional, independent eighth question to assess change in BPH-related health status (BHS) and quality of life. BHS scores range from 0 to 6, where 0 indicates &quot;delighted&quot; and 6 indicates &quot;terrible.&quot; The 7 items in the IPSS questionnaire quantitatively measure the level of urinary symptoms reported as a total IPSS. The total IPSS (sum of the first 7 items) can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35). Change from Baseline in IPSS total score was calculated as the Month 24 value minus the Baseline value. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in the Indicated Improvement Categories in the IPSS at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
    <description>Symptom improvement was assessed using IPSS categorical changes from Baseline. Change from Baseline categories were summarized by treatment group using five improvement levels: &gt;=1 point through &gt;=5 points. IPSS percent change from Baseline was summarized using seven improvement levels: &gt;0 percent, &gt;=10 percent, &gt;=20 percent, &gt;=25 percent, &gt;=30 percent, &gt;=40 percent, and &gt;=50 percent. Change in IPSS from Baseline was analysed using the LOCF method and is summarized for the following categories: &gt;=2 points, &gt;=3 points, and percent change &gt;=25. The 7 items in the IPSS questionnaire quantitatively measure the level of urinary symptoms reported as a total IPSS. The total IPSS (sum of the first 7 items) can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the BPH Impact Index (BII) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
    <description>The BII is a 4-item questionnaire covering physical discomfort, worry, bother, and impact on usual activities, with a minimum score of 0 (best) and a maximum score (worst) of 13 points. Individual missing questionnaire responses were imputed, as applicable. Change from Baseline in the BII score was summarized by treatment group using the LOCF approach at each scheduled post-Baseline assessment. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study. Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Cluster + Baseline Value. Baseline is defined as the Visit 2 value if it exists; otherwise, it is the latest of all Screening values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the BPH-related Health Status (BHS) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
    <description>Each participant was asked the following question &quot;If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?&quot;. This response was rated from 0 (&quot;delighted&quot;) to 6 (&quot;terrible&quot;). Change from Baseline in the BHS score was summarized by treatment group using the LOCF approach at each scheduled post-Baseline assessment. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study. Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Cluster + Baseline Value. Baseline is defined as the Visit 2 value if it exists; otherwise, it is the latest of all Screening values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Clinical Progression (CP) of BPH</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of participants with the first occurrence of clinical progression (CP) of BPH occurring on or after the randomization date are summarized by treatment and year. Time is based on the date of the first-occurring CP event, and is relative to the randomization date. CP of BPH is a composite of five endpoints assessed through the end of the study, including: symptom deterioration by IPSS &gt;=3 points from Baseline (Visit 2); acute urinary retention related to BPH; incontinence (overflow or urge) related to BPH; recurrent urinary tract infection (UTI) or urosepsis related to BPH; renal insufficiency related to BPH (a single &gt;=50% rise from Baseline serum creatinine and a total value &gt;=1.5 milligrams/deciliter). For components that required multiple episodes, the first of the multiple episodes was utilized in terms of timing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated First-occurring Component of Clinical Progression (CP) of BPH</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>CP of BPH is a composite of five endpoints assessed through the end of the study, including: symptom progression (symptom deterioration by IPSS &gt;=3 points from Baseline [Visit 2]); acute urinary retention (AUR) related to BPH; incontinence (overflow or urge) related to BPH; recurrent urinary tract infection (UTI) or urosepsis related to BPH; renal insufficiency related to BPH (a single &gt;=50% rise from Baseline serum creatinine and a total value &gt;=1.5 milligrams/deciliter). The number of participants with CP of BPH, the number of participants with the indicated first-occurring component of CP of BPH, the number of participants with two simultaneously first-occurring components (&quot;Tied for first component&quot;), and the number of participants with multiple first-occurring components were summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Any BPH-related Surgery, Who Had the Indicated Type of Surgery, Who Had 2 BPH-related Surgeries, and Who Had &gt;=3 BPH-related Surgeries</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>BPH-related surgery was summarized for events occurring on or after the date of randomization. The number of participants who had any BPH-related surgery, the indicated type of surgery, and multiple surgeries was summarized by treatment. Type of surgery data (cystoscopy, transurethral resection of the prostate [TURP], and prostatectomy) are presented in terms of the first-occurring BPH-related surgery after randomization. It was possible for a single participant to have multiple surgeries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Responses to Question 1 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
    <description>The PPST questionnaire consists of two questions (asked to determine how satisfied participants are with the treatment received) and was administered at Baseline and all post-Baseline visits. Question 1 was: &quot;Overall, how satisfied are you with the treatment and its effect on your urinary problems?&quot; There were seven possible responses, including: &quot;very satisfied,&quot; &quot;satisfied,&quot; &quot;somewhat satisfied,&quot; neutral,&quot; &quot;somewhat dissatisfied,&quot; &quot;dissatisfied,&quot; and &quot;very dissatisfied.&quot; Response categories were created by grouping together &quot;very satisfied,&quot; &quot;satisfied,&quot; and &quot;somewhat satisfied&quot; responses into the category of &quot;Any Satisfaction (AS),&quot; and separately grouping &quot;neutral,&quot; &quot;somewhat dissatisfied,&quot; &quot;dissatisfied,&quot; and &quot;very dissatisfied&quot; responses into the category of &quot;Neutral or Any Dissatisfaction (N/AD).&quot; The LOCF method involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Responses to Question 2 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</measure>
    <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
    <description>The PPST questionnaire consists of two questions (asked to determine how satisfied participants are with the treatment received) and was administered at Baseline and all post-Baseline visits. Question 2 was: &quot;Would you ask your doctor for the treatment you received in this study?&quot; There were three possible responses, including: &quot;Yes,&quot; &quot;No,&quot; and &quot;Not sure.&quot; Response categories included &quot;Yes&quot; and &quot;No or Not Sure,&quot; created by grouping together &quot;No&quot; and &quot;Not sure.&quot; The LOCF method involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to Study Drug</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Study drug exposure (days) = treatment stop date - treatment start date + 1. Participants in the Watchful Waiting Escalated=Yes subgroup could have been escalated to study drug at any time during the study. Therefore, it is possible that participants were exposed to tamsulosin for a shorter length of time than participants in the dutasteride plus tamsulosin group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Starting Post-randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>A post-randomization adverse event is defined as an event with an onset on or after the randomization date or with a missing onset date. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general non-serious AE/SAE module for a list of non-serious AEs (occurring at a frequency threshold of &gt;=5%) and SAEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">742</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Dutasteride plus tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dutasteride plus tamsulosin arm + lifestyle advice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Watchful waiting with escalation to tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Watchful waiting with escalation to tamsulosin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride plus tamsulosin</intervention_name>
    <description>Take 1 capsule daily</description>
    <arm_group_label>Dutasteride plus tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin</intervention_name>
    <description>Take 1 capsule daily when escalation criteria met</description>
    <arm_group_label>Watchful waiting with escalation to tamsulosin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Males aged ≥50 years.

          -  A confirmed clinical diagnosis of BPH.

          -  International Prostate Symptom Score (IPSS) 8−19 at Visit 1 (screening).

          -  Prostate volume ≥30 cc (by transrectal ultrasonography; TRUS).

          -  Total serum prostate specific antigen (PSA) ≥1.5 ng/mL at Visit 1 (screening).

          -  Willing and able to give signed written informed consent and comply with study
             procedures.

          -  Fluent and literate in local language with the ability to read, comprehend and record
             information on the IPSS and BII questionnaires.

          -  Able to swallow and retain oral medication.

          -  Willing and able to participate in the study for the full 2 years.

          -  Men with a female partner of childbearing potential must either agree to use effective
             contraception or have had a prior vasectomy. Contraception must be used from 2 weeks
             prior to administration of the first dose of study treatment until at least 5
             half-lives for the drug plus 3 months to allow clearance of any altered sperm after
             the last dose of study treatment.

          -  French subjects: In France, a subject will be eligible for inclusion in this study
             only if either affiliated to or a beneficiary of a social security category.

        Note: If total serum PSA is &gt;4 ng/mL and unless PSA value has been stable for at least the
        past 2 years, the investigator should make every appropriate effort to exclude the
        possibility of prostate cancer, e.g. further Digital rectal examination (DRE), review TRUS
        taken within previous month, consider 8−12 core prostate biopsy in accordance with routine
        clinical practice

        Exclusion Criteria:

          -  Subjects meeting any of the following criteria must not be enrolled in the study:

          -  Total serum PSA &gt;10.0 ng/mL at Visit 1 (screening).

          -  History or evidence of prostate cancer (e.g. positive biopsy or ultrasound within the
             previous 6 months, suspicious DRE and/or rising PSA).

        Excluded medication and therapies Current or any prior use of the following prohibited
        medications

          -  a 5α-reductase inhibitor (finasteride or dutasteride),

          -  anti-cholinergics (e.g. oxybutynin, propantheline)

          -  an alpha-adrenoreceptor blocker (i.e. indoramin, prazosin, terazosin, tamsulosin,
             alfuzosin and doxazosin) for BPH or Lower urinary tract symptoms (LUTS)

          -  any drugs with anti-androgenic properties (e.g. spironolactone, flutamide,
             bicalutamide, cimetidine, ketoconazole, progestational agents) within the previous 6
             months.

          -  any drugs noted for gynaecomastia effects, or could affect prostate volume, within 6
             months of the Visit 1

          -  any investigational or marketed study drug within 30 days or 5 half-lives, (whichever
             is longer), preceding the first dose of study treatment.

        Current use of:

          -  any alpha-adrenoreceptor blocker (i.e. indoramin, prazosin, terazosin, tamsulosin,
             alfuzosin and doxazosin)

          -  anabolic steroids.

          -  drugs known or thought to have an interaction with tamsulosin, e.g. cimetidine and
             warfarin.

          -  Use of phytotherapy for BPH within 2 weeks prior to Visit 1 (screening) and/or
             predicted to need phytotherapy during the study.

        Have a known (immediate or delayed) hypersensitivity reaction or idiosyncrasy to drugs
        chemically related to the study medication or excipients that, in the opinion of the
        Investigator or GlaxoSmithKline contraindicates their participation.

        Recent Medical Procedures

          -  Previous prostatic surgery (including TURP, balloon dilatation, thermotherapy and
             stent replacement) or other invasive or minimally invasive procedures to treat BPH.

          -  History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7
             days prior to Visit 1 (screening). Catheterisation (&lt;10F) is acceptable with no time
             restriction.

        Medical history

          -  History of AUR within 3 months prior to Visit 1 (screening).

          -  Post-void residual volume &gt;250 mL (suprapubic ultrasound) at Visit 1 (screening)..

          -  Any causes other than BPH, which may in the judgement of the investigator, result in
             urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck
             contracture, urethral stricture, bladder malignancy, acute or chronic prostatitis, or
             acute or chronic urinary tract infections).

          -  History of 'first dose' hypotensive episode on initiation of alpha-1-adrenoreceptor
             antagonist therapy for hypertension.

          -  History of postural hypotension, dizziness, vertigo or any other signs and symptoms of
             orthostasis, which in the opinion of the investigator could be exacerbated by
             tamsulosin and result in putting the subject at risk of injury.

          -  History of breast cancer or clinical breast examination finding of unclear origin or
             suggestive of malignancy.

          -  History of hepatic impairment or abnormal liver function tests at Visit 1 (screening).
             (defined as Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) or
             alkaline phosphatase &gt;2 times the Upper limit of normal (ULN) , or total bilirubin
             &gt;1.5 times the ULN, (unless associated with predominantly indirect bilirubin elevation
             or Gilbert's syndrome).

          -  History of renal insufficiency, or serum creatinine &gt;1.5 times the upper limit of
             normal at Visit 1 (screening)..

          -  Prior history of malignancies (other than basal cell carcinoma or squamous cell
             carcinoma of the skin) within the past 5 years. Subjects who have had no evidence of
             the malignancy for ≥5 years are eligible.

          -  History of any illness (including psychiatric) that in the opinion of the investigator
             might confound the results of the study or poses additional risk to the subject.

          -  Any unstable, serious co-existing medical condition(s) including, but not limited to,
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
             clinically evident congestive heart failure, or cerebrovascular accident within 6
             months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which
             is uncontrolled by medical management.

          -  History or current evidence of drug or alcohol abuse within the previous 12 months.

          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other
             conditions that could interfere with subject's safety, obtaining informed consent or
             compliance to the study procedures, in the opinion of the Investigator or GSK Medical
             Monitor.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aigrefeuille Sur Maine</city>
        <zip>44140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corsept</city>
        <zip>44560</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Montagne</city>
        <zip>44620</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Temple De Bretagne</city>
        <zip>44360</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murs Erigne</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nieul sur Mer</city>
        <zip>17137</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sautron</city>
        <zip>44880</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thouars</city>
        <zip>79100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tierce</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vihiers</city>
        <zip>49310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichach</city>
        <state>Bayern</state>
        <zip>86551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nuernberg</city>
        <state>Bayern</state>
        <zip>90441</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hagenow</city>
        <state>Brandenburg</state>
        <zip>19230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oranienburg</city>
        <state>Brandenburg</state>
        <zip>16515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strausberg</city>
        <state>Brandenburg</state>
        <zip>15344</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buchholz</city>
        <state>Niedersachsen</state>
        <zip>21244</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hettstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>06333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eisleben</city>
        <zip>06295</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Argos</city>
        <zip>21200</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>10552</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>151 26</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Larisa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Patra</city>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhodes</city>
        <zip>85100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vasto (CH)</city>
        <state>Abruzzo</state>
        <zip>66054</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Fermo della Battaglia (CO)</city>
        <state>Lombardia</state>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Foggia</city>
        <state>Puglia</state>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2582 LJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maarssen</city>
        <zip>3607 KN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voerendaal</city>
        <zip>6367 ED</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wildervank</city>
        <zip>9648 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winterswijk</city>
        <zip>7101 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arad</city>
        <zip>310175</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alava</city>
        <zip>01004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coslada</city>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fuenlabrada (Madrid)</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galdakano</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marbella</city>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendaro, Guipuzcoa</city>
        <zip>20850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastián</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chalfont St Giles</city>
        <state>Buckinghamshire</state>
        <zip>HP8 4QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sandbach</city>
        <state>Cheshire</state>
        <zip>CW11 1EQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broadway, Fleetwood</city>
        <zip>FY7 8GU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chadderton, Oldham</city>
        <zip>OL9 0LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>High Heaton, Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <results_first_submitted>May 15, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Treatment-naïve men with symptomatic benign prostatic hyperplasia (BPH) meeting eligibility criteria were enrolled and were randomized in a 1:1 ratio to receive dutasteride plus tamsulosin once daily plus lifestyle advice or watchful waiting plus lifestyle advice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dutasteride Plus Tamsulosin</title>
          <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Watchful Waiting All: Escalated Yes and No</title>
          <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="369"/>
                <participants group_id="P2" count="373"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dutasteride Plus Tamsulosin</title>
          <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Watchful Waiting All: Escalated Yes and No</title>
          <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="369"/>
            <count group_id="B2" value="373"/>
            <count group_id="B3" value="742"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="7.78"/>
                    <measurement group_id="B2" value="66.2" spread="7.34"/>
                    <measurement group_id="B3" value="66.2" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="373"/>
                    <measurement group_id="B3" value="742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="363"/>
                    <measurement group_id="B3" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward (LOCF) Approach</title>
        <description>The IPSS questionnaire is a 7-item self-administered questionnaire designed to quantify the following urinary symptoms: Question 1 (Q1), incomplete emptying; Q2, frequency; Q3, intermittency; Q4, urgency; Q5, weak stream; Q6, straining; Q7, nocturia. It has an additional, independent eighth question to assess change in BPH-related health status (BHS) and quality of life. BHS scores range from 0 to 6, where 0 indicates &quot;delighted&quot; and 6 indicates &quot;terrible.&quot; The 7 items in the IPSS questionnaire quantitatively measure the level of urinary symptoms reported as a total IPSS. The total IPSS (sum of the first 7 items) can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35). Change from Baseline in IPSS total score was calculated as the Month 24 value minus the Baseline value. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered. Any participant who received a treatment randomization number was considered to have been randomized. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward (LOCF) Approach</title>
          <description>The IPSS questionnaire is a 7-item self-administered questionnaire designed to quantify the following urinary symptoms: Question 1 (Q1), incomplete emptying; Q2, frequency; Q3, intermittency; Q4, urgency; Q5, weak stream; Q6, straining; Q7, nocturia. It has an additional, independent eighth question to assess change in BPH-related health status (BHS) and quality of life. BHS scores range from 0 to 6, where 0 indicates &quot;delighted&quot; and 6 indicates &quot;terrible.&quot; The 7 items in the IPSS questionnaire quantitatively measure the level of urinary symptoms reported as a total IPSS. The total IPSS (sum of the first 7 items) can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35). Change from Baseline in IPSS total score was calculated as the Month 24 value minus the Baseline value. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered. Any participant who received a treatment randomization number was considered to have been randomized. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1, n=358, 367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="0.21"/>
                    <measurement group_id="O2" value="-0.9" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.22"/>
                    <measurement group_id="O2" value="-2.4" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="0.23"/>
                    <measurement group_id="O2" value="-3.2" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="0.22"/>
                    <measurement group_id="O2" value="-3.6" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="0.23"/>
                    <measurement group_id="O2" value="-3.6" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="0.25"/>
                    <measurement group_id="O2" value="-3.6" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="0.25"/>
                    <measurement group_id="O2" value="-3.3" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="0.25"/>
                    <measurement group_id="O2" value="-3.6" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="0.25"/>
                    <measurement group_id="O2" value="-3.6" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 1</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 3</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 6</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 9</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 12</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 15</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 18</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 21</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Month 24</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Values are based on t-tests from the general linear model</method_desc>
            <param_type>Adjusted Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
            <estimate_desc>Estimates are based on the adjusted means from the general linear model: Change from Baseline = Treatment + Cluster + Baseline Value. The adjusted mean difference is based on dutasteride plus tamsulosin minus Watchful Waiting All.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in the Indicated Improvement Categories in the IPSS at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
        <description>Symptom improvement was assessed using IPSS categorical changes from Baseline. Change from Baseline categories were summarized by treatment group using five improvement levels: &gt;=1 point through &gt;=5 points. IPSS percent change from Baseline was summarized using seven improvement levels: &gt;0 percent, &gt;=10 percent, &gt;=20 percent, &gt;=25 percent, &gt;=30 percent, &gt;=40 percent, and &gt;=50 percent. Change in IPSS from Baseline was analysed using the LOCF method and is summarized for the following categories: &gt;=2 points, &gt;=3 points, and percent change &gt;=25. The 7 items in the IPSS questionnaire quantitatively measure the level of urinary symptoms reported as a total IPSS. The total IPSS (sum of the first 7 items) can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35).</description>
        <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in the Indicated Improvement Categories in the IPSS at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
          <description>Symptom improvement was assessed using IPSS categorical changes from Baseline. Change from Baseline categories were summarized by treatment group using five improvement levels: &gt;=1 point through &gt;=5 points. IPSS percent change from Baseline was summarized using seven improvement levels: &gt;0 percent, &gt;=10 percent, &gt;=20 percent, &gt;=25 percent, &gt;=30 percent, &gt;=40 percent, and &gt;=50 percent. Change in IPSS from Baseline was analysed using the LOCF method and is summarized for the following categories: &gt;=2 points, &gt;=3 points, and percent change &gt;=25. The 7 items in the IPSS questionnaire quantitatively measure the level of urinary symptoms reported as a total IPSS. The total IPSS (sum of the first 7 items) can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35).</description>
          <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1, &gt;=2 points, n=358, 367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, &gt;=3 points, n=358, 367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, &gt;=25 percent, n=358, 367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, &gt;=25 percent, n= 359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, &gt;=25 percent, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, &gt;=25 percent, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, &gt;=25 percent, n= 359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, &gt;=25 percent, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, &gt;=25 percent, 359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, &gt;=3 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, &gt;=25 percent, n= 359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, &gt;=2 points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, &gt;=3points, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, &gt;=25 percent, n= 359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the BPH Impact Index (BII) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
        <description>The BII is a 4-item questionnaire covering physical discomfort, worry, bother, and impact on usual activities, with a minimum score of 0 (best) and a maximum score (worst) of 13 points. Individual missing questionnaire responses were imputed, as applicable. Change from Baseline in the BII score was summarized by treatment group using the LOCF approach at each scheduled post-Baseline assessment. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study. Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Cluster + Baseline Value. Baseline is defined as the Visit 2 value if it exists; otherwise, it is the latest of all Screening values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the BPH Impact Index (BII) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
          <description>The BII is a 4-item questionnaire covering physical discomfort, worry, bother, and impact on usual activities, with a minimum score of 0 (best) and a maximum score (worst) of 13 points. Individual missing questionnaire responses were imputed, as applicable. Change from Baseline in the BII score was summarized by treatment group using the LOCF approach at each scheduled post-Baseline assessment. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study. Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Cluster + Baseline Value. Baseline is defined as the Visit 2 value if it exists; otherwise, it is the latest of all Screening values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1, n=357, 366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.11"/>
                    <measurement group_id="O2" value="-0.4" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.11"/>
                    <measurement group_id="O2" value="-1.0" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.11"/>
                    <measurement group_id="O2" value="-1.3" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.11"/>
                    <measurement group_id="O2" value="-1.5" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.12"/>
                    <measurement group_id="O2" value="-1.5" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.12"/>
                    <measurement group_id="O2" value="-1.5" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.12"/>
                    <measurement group_id="O2" value="-1.4" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="0.12"/>
                    <measurement group_id="O2" value="-1.6" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="0.12"/>
                    <measurement group_id="O2" value="-1.6" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the BPH-related Health Status (BHS) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
        <description>Each participant was asked the following question “If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?”. This response was rated from 0 (“delighted”) to 6 (“terrible”). Change from Baseline in the BHS score was summarized by treatment group using the LOCF approach at each scheduled post-Baseline assessment. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study. Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Cluster + Baseline Value. Baseline is defined as the Visit 2 value if it exists; otherwise, it is the latest of all Screening values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the BPH-related Health Status (BHS) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
          <description>Each participant was asked the following question “If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?”. This response was rated from 0 (“delighted”) to 6 (“terrible”). Change from Baseline in the BHS score was summarized by treatment group using the LOCF approach at each scheduled post-Baseline assessment. LOCF analysis involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study. Estimates are based on the adjusted means from the general linear model: Change from Baseline =Treatment + Cluster + Baseline Value. Baseline is defined as the Visit 2 value if it exists; otherwise, it is the latest of all Screening values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1, n=358, 367</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.06"/>
                    <measurement group_id="O2" value="-0.3" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.06"/>
                    <measurement group_id="O2" value="-0.7" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.06"/>
                    <measurement group_id="O2" value="-0.9" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.06"/>
                    <measurement group_id="O2" value="-1.0" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.06"/>
                    <measurement group_id="O2" value="-1.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.06"/>
                    <measurement group_id="O2" value="-1.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.06"/>
                    <measurement group_id="O2" value="-1.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.06"/>
                    <measurement group_id="O2" value="-1.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=359, 368</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.06"/>
                    <measurement group_id="O2" value="-1.1" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of Clinical Progression (CP) of BPH</title>
        <description>The number of participants with the first occurrence of clinical progression (CP) of BPH occurring on or after the randomization date are summarized by treatment and year. Time is based on the date of the first-occurring CP event, and is relative to the randomization date. CP of BPH is a composite of five endpoints assessed through the end of the study, including: symptom deterioration by IPSS &gt;=3 points from Baseline (Visit 2); acute urinary retention related to BPH; incontinence (overflow or urge) related to BPH; recurrent urinary tract infection (UTI) or urosepsis related to BPH; renal insufficiency related to BPH (a single &gt;=50% rise from Baseline serum creatinine and a total value &gt;=1.5 milligrams/deciliter). For components that required multiple episodes, the first of the multiple episodes was utilized in terms of timing.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>ITT Population. Only those participants at risk for CP at the specified visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Clinical Progression (CP) of BPH</title>
          <description>The number of participants with the first occurrence of clinical progression (CP) of BPH occurring on or after the randomization date are summarized by treatment and year. Time is based on the date of the first-occurring CP event, and is relative to the randomization date. CP of BPH is a composite of five endpoints assessed through the end of the study, including: symptom deterioration by IPSS &gt;=3 points from Baseline (Visit 2); acute urinary retention related to BPH; incontinence (overflow or urge) related to BPH; recurrent urinary tract infection (UTI) or urosepsis related to BPH; renal insufficiency related to BPH (a single &gt;=50% rise from Baseline serum creatinine and a total value &gt;=1.5 milligrams/deciliter). For components that required multiple episodes, the first of the multiple episodes was utilized in terms of timing.</description>
          <population>ITT Population. Only those participants at risk for CP at the specified visit were analyzed.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1, n=369, 373</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2, n=276, 251</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated First-occurring Component of Clinical Progression (CP) of BPH</title>
        <description>CP of BPH is a composite of five endpoints assessed through the end of the study, including: symptom progression (symptom deterioration by IPSS &gt;=3 points from Baseline [Visit 2]); acute urinary retention (AUR) related to BPH; incontinence (overflow or urge) related to BPH; recurrent urinary tract infection (UTI) or urosepsis related to BPH; renal insufficiency related to BPH (a single &gt;=50% rise from Baseline serum creatinine and a total value &gt;=1.5 milligrams/deciliter). The number of participants with CP of BPH, the number of participants with the indicated first-occurring component of CP of BPH, the number of participants with two simultaneously first-occurring components (&quot;Tied for first component&quot;), and the number of participants with multiple first-occurring components were summarized by treatment group.</description>
        <time_frame>Up to Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated First-occurring Component of Clinical Progression (CP) of BPH</title>
          <description>CP of BPH is a composite of five endpoints assessed through the end of the study, including: symptom progression (symptom deterioration by IPSS &gt;=3 points from Baseline [Visit 2]); acute urinary retention (AUR) related to BPH; incontinence (overflow or urge) related to BPH; recurrent urinary tract infection (UTI) or urosepsis related to BPH; renal insufficiency related to BPH (a single &gt;=50% rise from Baseline serum creatinine and a total value &gt;=1.5 milligrams/deciliter). The number of participants with CP of BPH, the number of participants with the indicated first-occurring component of CP of BPH, the number of participants with two simultaneously first-occurring components (&quot;Tied for first component&quot;), and the number of participants with multiple first-occurring components were summarized by treatment group.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with CP of BPH, n=369, 373</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH symptom progression, n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related AUR, n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related incontinence, n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent BPH-related UTI, n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related renal insufficiency, n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tied for first component, n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple components (2 components), n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple components (3 components), n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple components (&gt;=4 components), n=65, 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Any BPH-related Surgery, Who Had the Indicated Type of Surgery, Who Had 2 BPH-related Surgeries, and Who Had &gt;=3 BPH-related Surgeries</title>
        <description>BPH-related surgery was summarized for events occurring on or after the date of randomization. The number of participants who had any BPH-related surgery, the indicated type of surgery, and multiple surgeries was summarized by treatment. Type of surgery data (cystoscopy, transurethral resection of the prostate [TURP], and prostatectomy) are presented in terms of the first-occurring BPH-related surgery after randomization. It was possible for a single participant to have multiple surgeries.</description>
        <time_frame>Up to Month 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Any BPH-related Surgery, Who Had the Indicated Type of Surgery, Who Had 2 BPH-related Surgeries, and Who Had &gt;=3 BPH-related Surgeries</title>
          <description>BPH-related surgery was summarized for events occurring on or after the date of randomization. The number of participants who had any BPH-related surgery, the indicated type of surgery, and multiple surgeries was summarized by treatment. Type of surgery data (cystoscopy, transurethral resection of the prostate [TURP], and prostatectomy) are presented in terms of the first-occurring BPH-related surgery after randomization. It was possible for a single participant to have multiple surgeries.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with any BPH-related surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with cystoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TURP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with prostatectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with 2 surgeries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with &gt;=3 surgeries</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Responses to Question 1 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
        <description>The PPST questionnaire consists of two questions (asked to determine how satisfied participants are with the treatment received) and was administered at Baseline and all post-Baseline visits. Question 1 was: &quot;Overall, how satisfied are you with the treatment and its effect on your urinary problems?&quot; There were seven possible responses, including: &quot;very satisfied,&quot; &quot;satisfied,&quot; &quot;somewhat satisfied,&quot; neutral,&quot; &quot;somewhat dissatisfied,&quot; &quot;dissatisfied,&quot; and &quot;very dissatisfied.&quot; Response categories were created by grouping together &quot;very satisfied,&quot; &quot;satisfied,&quot; and &quot;somewhat satisfied&quot; responses into the category of &quot;Any Satisfaction (AS),&quot; and separately grouping &quot;neutral,&quot; &quot;somewhat dissatisfied,&quot; &quot;dissatisfied,&quot; and &quot;very dissatisfied&quot; responses into the category of &quot;Neutral or Any Dissatisfaction (N/AD).&quot; The LOCF method involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Responses to Question 1 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
          <description>The PPST questionnaire consists of two questions (asked to determine how satisfied participants are with the treatment received) and was administered at Baseline and all post-Baseline visits. Question 1 was: &quot;Overall, how satisfied are you with the treatment and its effect on your urinary problems?&quot; There were seven possible responses, including: &quot;very satisfied,&quot; &quot;satisfied,&quot; &quot;somewhat satisfied,&quot; neutral,&quot; &quot;somewhat dissatisfied,&quot; &quot;dissatisfied,&quot; and &quot;very dissatisfied.&quot; Response categories were created by grouping together &quot;very satisfied,&quot; &quot;satisfied,&quot; and &quot;somewhat satisfied&quot; responses into the category of &quot;Any Satisfaction (AS),&quot; and separately grouping &quot;neutral,&quot; &quot;somewhat dissatisfied,&quot; &quot;dissatisfied,&quot; and &quot;very dissatisfied&quot; responses into the category of &quot;Neutral or Any Dissatisfaction (N/AD).&quot; The LOCF method involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
          <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Any Satisfaction, n=315, 328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Neutral/Any Dissatisfaction, n=315, 328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Any Satisfaction, n=358, 349</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Neutral/Any Dissatisfaction, n=358, 349</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Any Satisfaction, n= 359, 359</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Neutral/Any Dissatisfaction, n=359, 359</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Any Satisfaction, n=359, 361</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Neutral /Any Dissatisfaction, n=359, 361</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Any Satisfaction, n=359, 361</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Neutral/Any Dissatisfaction, n= 359, 361</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Any Satisfaction, n=359, 363</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Neutral/Any Dissatisfaction, n=359, 363</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, Any Satisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, Neutral/Any Dissatisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, Any Satisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, Neutral/Any Dissatisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, Any Satisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, Neutral/Any Dissatisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, Any Satisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, Neutral/Any Dissatisfaction, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Responses to Question 2 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
        <description>The PPST questionnaire consists of two questions (asked to determine how satisfied participants are with the treatment received) and was administered at Baseline and all post-Baseline visits. Question 2 was: &quot;Would you ask your doctor for the treatment you received in this study?&quot; There were three possible responses, including: &quot;Yes,&quot; &quot;No,&quot; and &quot;Not sure.&quot; Response categories included &quot;Yes&quot; and &quot;No or Not Sure,&quot; created by grouping together &quot;No&quot; and &quot;Not sure.&quot; The LOCF method involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
        <time_frame>Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24</time_frame>
        <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Responses to Question 2 of the Patient Perception of Study Treatment (PPST) Questionnaire at Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the LOCF Approach</title>
          <description>The PPST questionnaire consists of two questions (asked to determine how satisfied participants are with the treatment received) and was administered at Baseline and all post-Baseline visits. Question 2 was: &quot;Would you ask your doctor for the treatment you received in this study?&quot; There were three possible responses, including: &quot;Yes,&quot; &quot;No,&quot; and &quot;Not sure.&quot; Response categories included &quot;Yes&quot; and &quot;No or Not Sure,&quot; created by grouping together &quot;No&quot; and &quot;Not sure.&quot; The LOCF method involves bringing forward the last non-missing post-Baseline assessment for a participant with missing data and/or for a participant who discontinued from the study.</description>
          <population>ITT Population. Participants with data available at the specified time point or using LOCF (post-Baseline) were summarized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Yes, n=315, 328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, No or Not Sure, n=315, 328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Yes, n=358, 347</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, No or Not Sure, n=358, 347</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Yes, n=359, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, No or Not Sure, n=359, 357</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Yes, n=359, 360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, No or Not Sure, n=359, 360</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, Yes, n=359, 361</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, No or Not Sure, n=359, 361</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Yes, n=359, 363</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, No or Not Sure, n=359, 363</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, Yes, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, No or Not Sure, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, Yes, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, No or Not Sure, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, Yes, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, No or Not Sure, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, Yes, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, No or Not Sure, n=359, 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exposure to Study Drug</title>
        <description>Study drug exposure (days) = treatment stop date - treatment start date + 1. Participants in the Watchful Waiting Escalated=Yes subgroup could have been escalated to study drug at any time during the study. Therefore, it is possible that participants were exposed to tamsulosin for a shorter length of time than participants in the dutasteride plus tamsulosin group.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Treated Subjects Population: all participants starting protocol pharmacological treatment, either dutasteride plus tamsulosin or (escalated to) tamsulosin, as indicated by a nonmissing electronic Case Report Form treatment start date</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting Escalated=Yes</title>
            <description>All participants were given lifestyle advice. If any IPSS was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure to Study Drug</title>
          <description>Study drug exposure (days) = treatment stop date - treatment start date + 1. Participants in the Watchful Waiting Escalated=Yes subgroup could have been escalated to study drug at any time during the study. Therefore, it is possible that participants were exposed to tamsulosin for a shorter length of time than participants in the dutasteride plus tamsulosin group.</description>
          <population>Treated Subjects Population: all participants starting protocol pharmacological treatment, either dutasteride plus tamsulosin or (escalated to) tamsulosin, as indicated by a nonmissing electronic Case Report Form treatment start date</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="639.8" spread="215.49"/>
                    <measurement group_id="O2" value="566.3" spread="195.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Starting Post-randomization</title>
        <description>A post-randomization adverse event is defined as an event with an onset on or after the randomization date or with a missing onset date. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general non-serious AE/SAE module for a list of non-serious AEs (occurring at a frequency threshold of &gt;=5%) and SAEs.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride Plus Tamsulosin</title>
            <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Watchful Waiting All: Escalated Yes and No</title>
            <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study. If participants did not receive tamsulosin, they were not classified as escalated (Watchful Waiting Escalated=No).</description>
          </group>
          <group group_id="O3">
            <title>Watchful Waiting Escalated=Yes</title>
            <description>All participants were given lifestyle advice. If any IPSS was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Starting Post-randomization</title>
          <description>A post-randomization adverse event is defined as an event with an onset on or after the randomization date or with a missing onset date. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment was exercised in deciding whether reporting was appropriate in other situations. Refer to the general non-serious AE/SAE module for a list of non-serious AEs (occurring at a frequency threshold of &gt;=5%) and SAEs.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="373"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious adverse events (AEs) starting post-randomization (including events with an onset on or after the randomization date or with a missing onset date) were collected (up to 2 years).</time_frame>
      <desc>SAEs and non-serious AEs are reported for members of the ITT Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dutasteride Plus Tamsulosin</title>
          <description>Participants received a combination of dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg plus lifestyle advice for 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Watchful Waiting All: Escalated Yes and No</title>
          <description>All participants were given lifestyle advice. If any International Prostate Symptom Score (IPSS) was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study.</description>
        </group>
        <group group_id="E3">
          <title>Watchful Waiting Escalated=Yes</title>
          <description>All participants were given lifestyle advice. If any IPSS was the same or greater than the Baseline value at any study visit (post-randomization), participants received tamsulosin 0.4 mg once daily (Watchful Waiting Escalated=Yes). Tamsulosin was continued until the end of the study unless the participant elected to withdraw from the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Myxoid liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Retrograde ejaculation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

